Phase I-IIa Clinical Trials: A Team You Can Trust
Experienced: One Core Team
ProMedica CRC, formerly a unit of MTRA, a pioneer in Phase I-IIa Clinical Trials, was established in 1996. Our clinical research team has been working with leading pharmaceutical, biotechnology, and medical device companies for nearly 40 years. This experience makes the difference.
Our Legacy
The core staff of ProMedica CRC has over 150 years of combined clinical research experience. Much of the senior staff has worked together in the industry since the early 1970s, including ProMedica CRC's CEO, President, and Medical Director.
Our Mission and Vision
ProMedica Clinical Research Center stands at the forefront of clinical research with our commitment to bring scientific integrity and reliability to the healthcare industry. Because safety is our paramount concern, we have chosen to focus on Phase I-IIa Clinical Studies, conducting only one study at a time. This unique approach affords us the opportunity to devote our full resources to each specific study, avoiding the compromise of any volunteer or study variables. ProMedica CRC chooses to focus on one study at a time, unlike most clinical research centers which are driven by volume.
Our Staff
Richard J. Parker, CEO and President is the founder of ProMedica CRC, and was also the founder and President of MTRA. He has over 40 years experience in the clinical research industry.
Tricia M. Fabrizio, Vice President, has over 35 years experience in the clinical research industry.
Miguel A. Zinny, MD, Medical Director, is Board Certified in Internal Medicine and Gastroenterology, and formerly the Medical Director of MTRA.
Maryellen Fitzgerald, MD, Associate Medical Director, is Board Eligible in Internal Medicine, and has 10 years of clinical research experience.
Brad Parker, Director of Business Development, has over 5 years of clinical research experience.